Abstract

BackgroundCD147 is an MMP-inducing protein often implicated in cancer progression. The purpose of this study was to investigate the expression of CD147 in prostate cancer (PCa) progression and the prognostic ability of CD147 in predicting biochemical recurrence after prostatectomy.MethodsPlasma membrane-localized CD147 protein expression was quantified in patient samples using immunohistochemistry and multispectral imaging, and expression was compared to clinico-pathological features (pathologic stage, Gleason score, tumor volume, preoperative PSA, lymph node status, surgical margins, biochemical recurrence status). CD147 specificity and expression were confirmed with immunoblotting of prostate cell lines, and CD147 mRNA expression was evaluated in public expression microarray datasets of patient prostate tumors.ResultsExpression of CD147 protein was significantly decreased in localized tumors (pT2; p = 0.02) and aggressive PCa (≥pT3; p = 0.004), and metastases (p = 0.001) compared to benign prostatic tissue. Decreased CD147 was associated with advanced pathologic stage (p = 0.009) and high Gleason score (p = 0.02), and low CD147 expression predicted biochemical recurrence (HR 0.55; 95 % CI 0.31–0.97; p = 0.04) independent of clinico-pathologic features. Immunoblot bands were detected at 44 kDa and 66 kDa, representing non-glycosylated and glycosylated forms of CD147 protein, and CD147 expression was lower in tumorigenic T10 cells than non-tumorigenic BPH-1 cells (p = 0.02). Decreased CD147 mRNA expression was associated with increased Gleason score and pathologic stage in patient tumors but is not associated with recurrence status.ConclusionsMembrane-associated CD147 expression is significantly decreased in PCa compared to non-malignant prostate tissue and is associated with tumor progression, and low CD147 expression predicts biochemical recurrence after prostatectomy independent of pathologic stage, Gleason score, lymph node status, surgical margins, and tumor volume in multivariable analysis.Electronic supplementary materialThe online version of this article (doi:10.1186/s12885-015-1559-4) contains supplementary material, which is available to authorized users.

Highlights

  • CD147 is an Matrix metalloproteinases (MMPs)-inducing protein often implicated in cancer progression

  • These results suggest that CD147 expression is decreased prostate cancer (PCa), with lower expression in advanced tumors and metastases

  • Our results show that CD147 is decreased in malignant prostate samples compared to tumor-adjacent normal tissue, and further decreases in expression are associated with advanced pathologic stage and Gleason score, indicating that CD147 may be important in the progression to advanced stages of PCa

Read more

Summary

Introduction

The purpose of this study was to investigate the expression of CD147 in prostate cancer (PCa) progression and the prognostic ability of CD147 in predicting biochemical recurrence after prostatectomy. Some patients experience biochemically recurrent disease, resulting in unfavorable prognosis and an estimated cancer-specific. Matrix metalloproteinases (MMPs) are proteinases that play a role in tissue remodeling and disease progression through regulation of the extracellular microenvironment. Previous studies have observed similar trends in PCa, with increased CD147 expression in PCa samples compared to matched benign samples and an association with poor prognosis after prostatectomy [9,10,11,12,13]. The purpose of this study was to investigate the prognostic role of CD147 in PCa and the expression of CD147 in PCa progression using quantitative multispectral imaging

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call